Posted by Michael Wonder on 19 Nov 2025
Lynkuet (elinzanetant) approved in the EU for the treatment of moderate to severe vasomotor symptoms associated with menopause or endocrine therapy for breast cancer
19 November 2025 - The European Commission has granted marketing authorisation in the European Union for elinzanetant, under the brand name Lynkuet.
The compound is approved for the treatment of moderate to severe vasomotor symptoms (also known as hot flashes) associated with menopause or caused by adjuvant endocrine therapy related to breast cancer.
